Photo: Teera Konakan/Getty Images
MD Integrations, a telemedicine API and white-label telehealth platform for physicians that allows providers to deliver compliant virtual care through their own brands, announced it secured $77 million from Updata Partners and Denali Growth Partners.
It also announced the appointment of Ramin Zacharia as its president and chief operating officer.
The company will use the funds to accelerate its growth.
"After helping build technology and provider networks at eight telehealth companies, I saw the need for a single solution that connects brands and their customers with high-quality care delivered only by doctors, integrated with a pharmacy network and powered by technology," Dr. Marc Serota, founder and CEO of MD Integrations, said in a statement.
"With MDI, we've created a scalable, trusted platform that unites physicians, pharmacies, and diagnostics in one system. This investment enables us to accelerate innovation and set the standard for physician-led virtual care."
Brook.ai, a company that combines remote clinical teams with AI to extend care to the home, has secured $28 million in Series B funding.
UMass Memorial Health and Morningside led the round.
"With this latest investment, we’re accelerating the growth of our commercial and care capabilities and actively building new partnerships with health systems nationwide. We’re looking for partners who share our mission of care continuity, extending care beyond clinic walls to drive engagement and improve health outcomes," Oren Nissim, CEO and cofounder of Brook.ai, told MobiHealthNews.
"We’re scaling what’s already proven to work: expanding into new populations, advancing our AI-driven platform and growing our teams to meet the strong demand we’re seeing in the market."
Counsel Health, a company that offers an AI-enabled asynchronous care platform that provides medical advice from real clinicians to patients via messaging, secured $25 million in Series A funding.
Andreessen Horowitz (a16z) and GV (Google Ventures) led the round.
The New York-based company will use the funds to grow its physician network, invest in AI and develop enterprise partnerships with employers, payers and provider groups.
"Counsel is reimagining care delivery in an AI-native world: scalable, evidence-based and accessible. We’re excited to back this team that brings a unique blend of clinical insight and AI fluency to set a new standard for care," Julie Yoo, general partner at a16z, said in a statement.
The raise comes one year after Counsel received $11 million in funding in a round led by Andreessen Horowitz ("a16z") Bio + Health.
OutcomesAI, which combines AI voice agents with licensed nurses to deliver care across pharma, health systems and virtual care settings, garnered $10 million in seed funding.
Santé Ventures led the round, and the company will use the funds to speed up its commercial rollout, expand its partnerships and launch dedicated nursing services lines.
"Healthcare is running out of nursing capacity, and incremental fixes won’t solve it," Kuldeep Singh Rajput, founder and CEO of OutcomesAI, said in a statement.
"With OutcomesAI, we’re not replacing nurses — we’re multiplying them. By combining AI voice agents with licensed nursing teams, we give back time to the people at the center of care, reduce burnout, and build a sustainable, scalable model for the future."
Smartlens, which offers ophthalmic technology to advance glaucoma management devices, has closed an oversubscribed $5.2 million bridge round led by Ambit Health Ventures.
Existing investors Graphene Ventures and Boutique Venture Partners, along with new investors Harvard Business School Alumni Angels GNY and a group of leading eye care providers, participated in the round.
The company's technology miLens is an electronics-free contact lens used for continuous intraocular pressure (IOP) monitoring. It is a wearable microfluidic device that works with Smartlens' AI-enabled smartphone imaging platform, capturing pressure fluctuations to enable data-driven treatment.
The company will use the funds to advance FDA clearance and for market launch.
"This financing milestone strengthens our position as we advance through the FDA clearance process and prepare for commercialization," Savas Komban, CEO and cofounder of Smartlens, said in a statement.
"We're laying the foundation for the next generation of glaucoma management — one driven by continuous, data-based insight rather than intermittent snapshots. The continued confidence from our investors underscores both the scale of the opportunity ahead and the meaningful impact miLens can have for patients worldwide."
